Eli Lilly Reports Dosing of its First Patient with Tirzepatide

Shots: The P-III SURPASS-CVOT study involves assessing non-inferiority and superiority of tirzepatide vs Trulicity (dulaglutide, 15mg) in 12,500 patients with T2D and atherosclerotic cardiovascular disease from 30 countries. The company expects for the completion of trial in four years The 1EPs will measure time to first occurrence of MACE-3, the composite endpoint of CV death, […]Read More